Snippet from the article:
The prostate cancer drug Xtandi prolonged lives and delayed tumor progression when used before chemotherapy in a study of men with advanced cases of the disease, researchers said on Tuesday. The study results are expected to open up a broader market for Xtandi, which was developed by Medivation and Astellas Pharma, and open a new front in its competition with Johnson & Johnson’s blockbuster drug Zytiga.
Xtandi, also known as enzalutamide, was approved in 2012 as a treatment for men with metastatic prostate cancer who have already tried the chemotherapy drug docetaxel. The new study showed it was also effective when used before chemotherapy.
Doctors said that could be a welcome option for the tens of thousands of men each year who have advanced prostate cancer but little or no pain or other symptoms. Many of them would rather take a pill like Xtandi or Zytiga than go for periodic infusions of chemotherapy, with its harsh side effects.